Predicting Patient Response To Gleevec In Gastrointestinal Stromal Tumors, Fox Chase Cancer Center Study
Fox Chase Cancer Center -- PHILADELPHIA (April 21, 2009) – Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.